High-concentration of BMP2 reduces cell proliferation and increases apoptosis via DKK1 and SOST in human primary periosteal cells

Bone

Volumn 54, Issue 1, 2013, Pages 141-150

  Kim, Harry K W ^a,b   Oxendine, Ila ^a   Kamiya, Nobuhiro ^a,b  

^a TEXAS SCOTTISH RITE HOSPITAL FOR CHILDREN   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

DKK1; High concentration BMP2; Periosteum; Proliferation; SOST; Wnt

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; CASPASE; DICKKOPF 1 PROTEIN; SCLEROSTIN; SMALL INTERFERING RNA; WNT PROTEIN;

APOPTOSIS; ARTICLE; BONE CELL; CELL ASSAY; CELL ISOLATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; PERIOSTEUM; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; WNT SIGNALING PATHWAY;

APOPTOSIS; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEINS; CASPASES; CELL PROLIFERATION; CELLS, CULTURED; GENETIC MARKERS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, BIOLOGICAL; PERIOSTEUM; RNA, SMALL INTERFERING; WNT PROTEINS;

EID: 84874537755     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.01.031     Document Type: Article

References (47)

1. Urist M.R. Bone: formation by autoinduction. Science 1965, 150(698):893-899.
2. Sampath T.K., Reddi A.H. Dissociative extraction and reconstitution of extracellular matrix components involved in local bone differentiation. Proc Natl Acad Sci U S A 1981, 78(12):7599-7603.
3. Wozney J.M., Rosen V., Celeste A.J., Mitsock L.M., Whitters M.J., Kriz R.W., et al. Novel regulators of bone formation: molecular clones and activities. Science 1988, 242(4885):1528-1534.
4. Luyten F.P., Cunningham N.S., Ma S., Muthukumaran N., Hammonds R.G., Nevins W.B., et al. Purification and partial amino acid sequence of osteogenin, a protein initiating bone differentiation. J Biol Chem 1989, 264(23):13377-13380.
5. Wozney J.M. The bone morphogenetic protein family and osteogenesis. Mol Reprod Dev 1992, 32(2):160-167.
6. Gupta M.C., Khan S.N. Application of bone morphogenetic proteins in spinal fusion. Cytokine Growth Factor Rev 2005, 16(3):347-355.
7. Garrison K.R., Donell S., Ryder J., Shemilt I., Mugford M., Harvey I., et al. Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the non-healing of fractures and spinal fusion: a systematic review. Health Technol Assess 2007, 11(30):1-168.
8. White A.P., Vaccaro A.R., Hall J.A., Whang P.G., Friel B.C., McKee M.D. Clinical applications of BMP-7/OP-1 in fractures, nonunions and spinal fusion. Int Orthop 2007, 31(6):735-741.
9. Woo E.J. Recombinant human bone morphogenetic protein-2: adverse events reported to the Manufacturer and User Facility Device Experience database. Spine J 2012, 12(10):894-899.
10. Woo EJ. Adverse events after recombinant human BMP2 in nonspinal orthopaedic procedures. Clin Orthop Relat Res in press.
11. Woo E.J. Adverse events reported after the use of recombinant human bone morphogenetic protein 2. J Oral Maxillofac Surg 2012, 70(4):765-767.
12. Carragee E.J., Hurwitz E.L., Weiner B.K. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 2011, 11(6):471-491.
13. Dmitriev A.E., Lehman R.A., Symes A.J. Bone morphogenetic protein-2 and spinal arthrodesis: the basic science perspective on protein interaction with the nervous system. Spine J 2011, 11(6):500-505.
14. Williams B.J., Smith J.S., Fu K.M., Hamilton D.K., Polly D.W., Ames C.P., et al. Does bone morphogenetic protein increase the incidence of perioperative complications in spinal fusion? A comparison of 55,862 cases of spinal fusion with and without bone morphogenetic protein. Spine (Phila Pa 1976) 2011, 36(20):1685-1691.
15. Mroz T.E., Wang J.C., Hashimoto R., Norvell D.C. Complications related to osteobiologics use in spine surgery: a systematic review. Spine (Phila Pa 1976) 2010, 35(Suppl. 9):S86-S104.
16. Pradhan B.B., Bae H.W., Dawson E.G., Patel V.V., Delamarter R.B. Graft resorption with the use of bone morphogenetic protein: lessons from anterior lumbar interbody fusion using femoral ring allografts and recombinant human bone morphogenetic protein-2. Spine (Phila Pa 1976) 2006, 31(10):E277-E284.
17. Lee K.B., Taghavi C.E., Murray S.S., Song K.J., Keorochana G., Wang J.C. BMP induced inflammation: a comparison of rhBMP-7 and rhBMP-2. J Orthop Res 2012.
18. Mindea S.A., Shih P., Song J.K. Recombinant human bone morphogenetic protein-2-induced radiculitis in elective minimally invasive transforaminal lumbar interbody fusions: a series review. Spine (Phila Pa 1976) 2009, 34(14):1480-1484. [discussion 1485].
19. Shields L.B., Raque G.H., Glassman S.D., Campbell M., Vitaz T., Harpring J., et al. Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine (Phila Pa 1976) 2006, 31(5):542-547.
20. Tumialan L.M., Rodts G.E. Adverse swelling associated with use of rh-BMP-2 in anterior cervical discectomy and fusion. Spine J 2007, 7(4):509-510.
21. Rihn J.A., Makda J., Hong J., Patel R., Hilibrand A.S., Anderson D.G., et al. The use of RhBMP-2 in single-level transforaminal lumbar interbody fusion: a clinical and radiographic analysis. Eur Spine J 2009, 18(11):1629-1636.
22. Joseph V., Rampersaud Y.R. Heterotopic bone formation with the use of rhBMP2 in posterior minimal access interbody fusion: a CT analysis. Spine (Phila Pa 1976) 2007, 32(25):2885-2890.
23. Carragee E.J., Mitsunaga K.A., Hurwitz E.L., Scuderi G.J. Retrograde ejaculation after anterior lumbar interbody fusion using rhBMP-2: a cohort controlled study. Spine J 2011, 11(6):511-516.
24. FDA InFUSE Bone Graft/LT-CAGE Lumbar Tapered Fusion Device. Summary of safety and effective data premarket approval application P000058, Rockville, MD 2002.
25. Wu D.T., Bitzer M., Ju W., Mundel P., Bottinger E.P. TGF-beta concentration specifies differential signaling profiles of growth arrest/differentiation and apoptosis in podocytes. J Am Soc Nephrol 2005, 16(11):3211-3221.
26. Massague J. Receptors for the TGF-beta family. Cell 1992, 69(7):1067-1070.
27. Kamiya N., Jikko A., Kimata K., Damsky C., Shimizu K., Watanabe H. Establishment of a novel chondrocytic cell line N1511 derived from p53-null mice. J Bone Miner Res 2002, 17(10):1832-1842.
28. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25(4):402-408.
29. Zhang C., Cho K., Huang Y., Lyons J.P., Zhou X., Sinha K., et al. Inhibition of Wnt signaling by the osteoblast-specific transcription factor Osterix. Proc Natl Acad Sci U S A 2008, 105(19):6936-6941.
30. Baron R., Rawadi G., Roman-Roman S. Wnt signaling: a key regulator of bone mass. Curr Top Dev Biol 2006, 76:103-127.
31. Kamiya N., Kobayashi T., Mochida Y., Yu P.B., Yamauchi M., Kronenberg H.M., et al. Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the Type IA receptor (BMPRIA) in osteoblasts. J Bone Miner Res 2010, 25(2):200-210.
32. Allen M.R., Hock J.M., Burr D.B. Periosteum: biology, regulation, and response to osteoporosis therapies. Bone 2004, 35(5):1003-1012.
33. Schmitt J.M., Hwang K., Winn S.R., Hollinger J.O. Bone morphogenetic proteins: an update on basic biology and clinical relevance. J Orthop Res 1999, 17(2):269-278.
34. Valentin-Opran A., Wozney J., Csimma C., Lilly L., Riedel G.E. Clinical evaluation of recombinant human bone morphogenetic protein-2. Clin Orthop Relat Res 2002, 395:110-120.
35. Khosla S., Westendorf J.J., Oursler M.J. Building bone to reverse osteoporosis and repair fractures. J Clin Invest 2008, 118(2):421-428.
36. David L., Feige J.J., Bailly S. Emerging role of bone morphogenetic proteins in angiogenesis. Cytokine Growth Factor Rev 2009, 20(3):203-212.
37. Garrison K.R., Shemilt I., Donell S., Ryder J.J., Mugford M., Harvey I., et al. Bone morphogenetic protein (BMP) for fracture healing in adults. Cochrane Database Syst Rev 2010, (6):CD006950.
38. Starman J.S., Bosse M.J., Cates C.A., Norton H.J. Recombinant human bone morphogenetic protein-2 use in the off-label treatment of nonunions and acute fractures: a retrospective review. J Traumatol Acute Care Surg 2012, 72(3):676-681.
39. Aro H.T., Govender S., Patel A.D., Hernigou P., Perera de Gregorio A., Popescu G.I., et al. Recombinant human bone morphogenetic protein-2: a randomized trial in open tibial fractures treated with reamed nail fixation. J Bone Joint Surg Am 2011.
40. Seeherman H.J., Li X.J., Bouxsein M.L., Wozney J.M. rhBMP-2 induces transient bone resorption followed by bone formation in a nonhuman primate core-defect model. J Bone Joint Surg Am 2010, 92(2):411-426.
41. Zara J.N., Siu R.K., Zhang X., Shen J., Ngo R., Lee M., et al. High doses of bone morphogenetic protein 2 induce structurally abnormal bone and inflammation in vivo. Tissue Eng Part A 2011, 17(9-10):1389-1399.
42. Steven Gitelis M., Ross M., Wilkins M., Alan M., Yasko W. BMPs and cancer: is the risk real. AAOS Now 2008, 2(5). [http://www.aaos.org/news/aaosnow/may08/research7.asp].
43. Kamiya N., Ye L., Kobayashi T., Mochida Y., Yamauchi M., Kronenberg H.M., et al. BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. Development 2008, 135(22):3801-3811.
44. Kamiya N., Kaartinen V.M., Mishina Y. Loss-of-function of ACVR1 in osteoblasts increases bone mass and activates canonical Wnt signaling through suppression of Wnt inhibitors SOST and DKK1. Biochem Biophys Res Commun 2011, 414(2):326-330.
45. Kamiya N. The role of BMPs in bone anabolism and their potential targets SOST and DKK1. Curr Mol Pharmacol 2012, 5(2):153-163.
46. Bodine P.V. Wnt signaling control of bone cell apoptosis. Cell Res 2008, 18(2):248-253.
47. van Bezooijen R.L., Roelen B.A., Visser A., van der Wee-Pals L., de Wilt E., Karperien M., et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 2004, 199(6):805-814.